Drug treatment of glaucoma focuses on reducing / controlling IOP and preserving visual function. Given the availability of therapies from several drug classes (e.g., PGAs, beta blockers, FDCs), multiple factors (e.g., efficacy, safety / tolerability, patient convenience and compliance, cost) determine the treatment approach. Even with multiple generic therapies available, branded therapies (e.g., Allergan’s Lumigan and Combigan, Novartis’s Travatan Z) still play an important role in glaucoma treatment. Given the continued use of branded therapies and the entry of new agents to the market (e.g., Bausch + Lomb’s Vyzulta, Aerie Pharmaceuticals’ Rhopressa), it is essential to understand physicians’ actual prescribing behavior for glaucoma.

QUESTIONS ANSWERED

  • What percentage of glaucoma patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What patient share do key therapies, including newer-to-market agents Vyzulta and Rhopressa, garner by line of therapy in newly diagnosed glaucoma patients?
  • What key drug classes and brands compete for share among recently treated patients? What are the quarterly trends in prescribing for these patients?
  • What percentage of glaucoma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients with glaucoma?

CONTENT HIGHLIGHTS

Geography: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Lumigan, Travatan Z, Combigan, Cosopt PF, Simbrinza, Alphagan P, Azopt, Vyzulta, Rhopressa, latanoprost, timolol maleate

Key analysis provided:

  • Brand/therapy usage across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Glaucoma - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Author(s): Himanshu Jain, M.S. Pharm

Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis.

Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a M.S. degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.


Related Reports

Glaucoma - Special Topics - Special Topics | New And Innovative Approaches In Treating Glaucoma (U.S.)

The primary goal of glaucoma treatment is to reduce an...

View Details